Core Alternative Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$37.6K Hold
620
0.01% 153
2025
Q4
$33.4K Sell
620
-80
-11% -$3.85K 0.01% 155
2025
Q3
$31.6K Hold
700
0.01% 147
2025
Q2
$32.4K Hold
700
0.01% 148
2025
Q1
$42.7K Hold
700
0.01% 137
2024
Q4
$39.6K Hold
700
0.01% 152
2024
Q3
$36.2K Hold
700
0.01% 155
2024
Q2
$29.1K Hold
700
0.01% 171
2024
Q1
$38K Sell
700
-992
-59% -$50.5K 0.01% 158
2023
Q4
$86.8K Sell
1,692
-2,088
-55% -$110K 0.01% 137
2023
Q3
$219K Sell
3,780
-68
-2% -$4.17K 0.03% 115
2023
Q2
$246K Buy
3,848
+8
+0.2% +$536 0.04% 90
2023
Q1
$266K Sell
3,840
-179
-4% -$12.6K 0.04% 84
2022
Q4
$289K Buy
4,019
+2,653
+194% +$200K 0.04% 93
2022
Q3
$97K Buy
1,366
+66
+5% +$4.79K 0.02% 110
2022
Q2
$100K Buy
1,300
+180
+16% +$13.7K 0.02% 116
2022
Q1
$82K Buy
1,120
+674
+151% +$45.3K 0.02% 123
2021
Q4
$28K Buy
446
+97
+28% +$5.69K 0.01% 128
2021
Q3
$21K Buy
+349
New +$23K ﹤0.01% 90

Other funds holding BMY

Core Alternative Capital's BMY Position: Q1 2026 in Review

Core Alternative Capital held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 620 shares worth $37.6K. The position accounts for 0.01% of the portfolio, ranked #153.

Core Alternative Capital first reported a position in BMY in Q3 2021 and has held it in 19 quarters since. The position peaked at $289K in Q4 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Core Alternative Capital held 620 shares of Bristol-Myers Squibb worth $37.6K as of Q1 2026.
  • Core Alternative Capital left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.01% of Core Alternative Capital's portfolio in Q1 2026, its #153 holding.
  • Core Alternative Capital first reported a position in Bristol-Myers Squibb in Q3 2021 and has held it in 19 quarters since.
  • Core Alternative Capital's Bristol-Myers Squibb position peaked at $289K in Q4 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Core Alternative Capital's 13F filing for Q1 2026, filed 30 Apr 2026.